ISSN: 0973-7510

E-ISSN: 2581-690X

Research Article | Open Access
Kaoutar Bouriat1,2, Soumia Cherif1,3, Souad Sellami2, Maria Dref2, Khadija Krati4, Meftah Elkhir Meriem1, Said Elantri1, Abdessamad Amine1 and Hanane Rais2
1Laboratory of Biochemistry, Environment, and Agrifood, Faculty of Sciences and Techniques-Mohammedia, University of Hassan II of Casablanca, Morocco.
2Department of Anatomy-pathology, The Arrazi Hospital CHU Mohammed VI of Marrakech, Morocco.
3Clinic of Gynecology, Charite -Universitatsmedizin, Berlin, Germany.
4Department of Gastroenterology, The Arrazi Hospital CHU Mohammed VI of Marrakech, Morocco.
J Pure Appl Microbiol. 2022;16(1):717-728 | Article Number: 7361 | © The Author(s). 2022
Received: 06/10/2021 | Accepted: 26/01/2022 | Published online: 25/02/2022
Issue online: March 2022

Observational studies regarding the correlation between colorectal carcinoma, inflammatory bowel disease and Helicobacter pylori infection are inconsistent. The present study aims to investigate the association between colorectal adenocarcinoma (CRA) and inflammatory bowel disease (IBD) with H. pylori status in 100 patients who have inflammatory bowel disease and colorectal carcinoma was confirmed disease by histological approach. Besides, a meta-analysis was performed of published studies, to evaluate the link between H. pylori infection and an increased risk of CRC and IBD. Among 67 cases with CRA and 33 cases with IBD, 59.7% and 51.5% were H. pylori positive; respectively. In the meta-analysis, thirty-nine articles were included, involving 13 231 cases with CRC and 2477 with IBD. The pooled odds ratio for CRC and IBD was 1.16 (95%CI = 0.73-1.82) and 0.42 (95%CI = 0.32-0.56); respectively. Our meta-analysis indicates that H. pylori is not associated with CRC.


Colorectal adenocarcinoma, colorectal cancer, Helicobacter pylori, IBD, immunohistochemistry, meta-analysis

Article Metrics

Article View: 90

Share This Article

© The Author(s) 2022. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.